Influence of lidocaine on ouabain-induced inotropic response in rat atria

Biochemical Pharmacology

Volumn 66, Issue 9, 2003, Pages 1871-1877

  Sterin Borda, Leonor ^a   Orman, Betina ^a   Reina, Silvia ^a   Borda, Enri ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Binding assay; Contractility; Heart; Lidocaine; Ouabain

Indexed keywords

2 [2 [4 (4 NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA METHANESULFONATE; CALCIUM; CALCIUM CHANNEL; CALMODULIN; FLUNARIZINE; LIDOCAINE; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; OUABAIN; SODIUM CHANNEL; VERAPAMIL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CARDIOTOXICITY; CONTRACTURE; CONTROLLED STUDY; HEART ARRHYTHMIA; HEART ATRIUM; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0141888281     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00554-9     Document Type: Article

References (44)

1. Reiser H.J., Sullivan M.E. Antiarrhythmic drug therapy: new drugs and changing concepts. Fed. Proc. 45:1986;2206-2222.
2. Singh B.N., Collet J.T., Chew C.Y.C. New perspectives in the pharmacological therapy of cardiac arrhythmias. Prog. Cardiovasc. Dis. 22:1980;243-248.
3. Hanck D.A., Makielski J.C., Sheets M.F. Lidocaine alters activation gating of cardiac sodium channels. Pflugers Arch.-Eur. J. Physiol. 439:2000;814-821.
4. Goldman S., Heger D., Olajos M., Perrier D., Mayersohn M. Effect of ouabain-quinidine interaction on left ventricular and left atrial function in conscious dogs. Circulation. 67:1983;1054-1058.
5. Kane K.A., Berdeja García G.Y., Sánchez Pérez S., Pastelin G. Electrophysiological effects of lidocaine, I - Chlorpheniramine and bepridil on normal and ouabain-intoxicated canine Purkinge fibres. J. Cardiovas Pharmacol. 5:1983;109-115.
6. Atkinson A.J., Davinson R. Diphenylhydantoin as an antiarrhythmic drug. Ann. Rev. Med. 25:1974;99-103.
7. Wit A.L., Rosen M.R., Hoffman B.F. Electrophysiology and pharmacology of cardiac arrhythmias. Am. Heart J. 90:1975;265-272.
8. Rosen M.R. Cardiac arrhythmias an antiarrhythmic drugs: recent advances in our understanding of mechanism. J. Cardiovasc. Electrophysiol. 6:1995;868-879.
9. Kotyk A., Amler E. Na,K-adenosinetriphosphatase: the paradigm of a membrane transport protein. Phys. Res. 44:1995;261-274.
10. Smith T.W., Antman E.M., Friedman P.L., Blatt C.M., Marsch J.D. Digitals glycosides: mechanism and manifestation of toxicity. Prog. Cardiovasc. Dis. 26:1984;495-540.
11. Kimura J., Miyamae S., Noma A. Identification of sodium-calcium exchange current in single ventricular cells of guinea pig. J. Physiol. (London). 384:1987;199-222.
12. 2+ exchanger is essential for the action of cardiac glycosides. J. Cardiovasc. Electrophysiol. 12:2001;1295-1301.
13. 2+ exchange inhibitor, KB-R7943 on ouabain-induced arrhythmias in guinea pigs. Br. J. Pharmacol. 127:1999;1846-1850.
14. Xie Z. Ouabain interaction with cardiac Na/K/ATPase-reveals that the enzyme can act as a pump and as a signal transducer. Cell Mol. Biol. 47:2001;383-390.
15. +-adenosine triphosphatase from different species. Biochem. Pharmacol. 21:1972;1553-1560.
16. Langer G.A., Brady A.J., Serena S.D. Correlation of the glycoside response, the force staircase and the action potential configuration in the neonatal rat heart. Circ. Res. 36:1975;744-752.
17. Erdmann E, Brown L, Werdan K. Two receptors for cardiac glycosides in the heart. In: Erdmann E, editor. Cardiac glycoside receptors and positive inotropy, evidence for more than one receptor? Darmstadt: Steinkopff Verlag; 1984. p. 21-34.
18. Canga L., Sterin-Borda L., Gimeno A.L. Extracellular calcium concentration and calcium blocking agents on the action of ouabain on isolated rat atrium. Pharmacol. Res. Commun. 14:1982;15-30.
19. Sterin-Borda L., Cantore M., Pascual J., Borda E., Cossio P., Arana R., Passeron S. Chagasic IgG binds and interacts with cardiac beta adrenoceptor-coupled adenylate cyclase system. Int. J. Immunopharmacol. 8:1986;561-588.
20. Borda E., Pascual J., Cossio P., De la Vega M., Arana R., Sterin-Borda L. A circulating IgG in Chagas disease which binds to beta adrenoceptors of miocardium and modulates their activity. Clin. Exp. Immunol. 57:1984;679-686.
21. Van Rossum J.M. Cumulative dose-response curves. Arch. Int. Pharmacodyn. Ther. 143:1963;299-330.
22. Goin J.C., Borda E., Perez Leiros C., Storino R., Sterin-Borda L. Identification of antibodies with muscarinic cholinergic activity in human Chagas disease: pathological implications. J. Aut. Nerv. Syst. 47:1994;45-52.
23. +-ATPase inhibition in microsomes from rat heart. Biochem. Pharmacol. 33:1984;47-53.
24. +-ATPase activity. Res. Commun. Pathol. Pharmacol. 69:1990;253-256.
25. Brown L., Erdmann E. Two binding sites for ouabain in cardiac cell membranes. Basic Res. Cardiol. 79:1984;50-55.
26. +-ATPase. Can. J. Physiol. Pharmacol. 77:1999;866-870.
27. +-ATPase in guinea pig heart preparations. Gen. Pharmacol. 22:1991;403-406.
28. Dzimiri M. Effects of procainamide, tocainide and phenytoin on guinea pig cardiac mitochondrial ATPase activity. Res. Commun. Chem. Pathol. Pharmacol. 80:1993;121-124.
29. Kyte J. Molecular considerations relevant to the mechanism of active transport. Nature (London). 292:1981;201-204.
30. Kass R.S., Tsien R.W., Weingart R. Ionic basis of transient inward current induced by strophanthidin in cardiac Purkinje fibres. J. Physiol. (London). 281:1978;209-226.
31. Smith T.W., Antman E.M., Friedman P.L., Blatt C.M., Marsch J.D. Digitalis glycosides: mechanism and manifestation of toxicity. Prog. Cardiovasc. Dis. 26:1984;495-540.
32. Kotyk A., Amler E. Na, K-adenosinetriphosphatase: the paradigm of a membrane transport protein. Phys. Res. 4:1995;261-274.
33. +-ATPase activity and force of contraction in rat heart. Biochem. Pharmacol. 29:1980;3119-3129.
34. + transporting ATPase from human and guinea pig muscle through use of digitalis derivatives as analytic probes. Naunyn Schmiedeberg's Arch. Pharmacol. 351:1995;282-292.
35. Charlemagne D. Molecular and cellular level of action of digitalis. Herz. 18:1993;79-85.
36. Wilson R.A., Soei L.K., Besztarosti K., Lamers J.M., Verdour P.D. Negative inotropy of lidocaine: possible biochemical mechanism. Eur. Heart J. 14:1993;284-289.
37. Schlepper M. Cardiodepressive effect of antiarrhythmic drugs. Eur. Heart J. 10:1989;73-80.
38. Simaan J.A. Influence of pretreatment with pheytoin, lidocaine and quinidine on the cardiodynamic and electrophysiological effects of ouabain in the cat heart-lung preparation. Arch. Int. Pharmacodyn. Ther. 324:1993;47-59.
39. Borst C., Heeeempelmann R., Herzigg S., Mohr K. Modulation of ouabain binding in beating ventricular myocardium from guinea pigs: effects of lidocaine and monensin. Pharmacol. Toxicol. 68:1991;243-248.
40. Vos M.A., Gorgels A.P., Leunissen J.D., van der Nagel T., Halbertsma F.J., Wellens H.J. Further observations to confirm the arrhythmia mechanism-specific effects of flunarizine. J. Cardiovasc. Pharmacol. 19:1992;682-690.
41. +-channel blockers in isolated Purkinje neurons of rat cerebellum. Neuroscience. 54:1993;575-585.
42. Jonkman F.A.M., Boddeke H.W.G., Van Zwieten P.A. Protective activity of calcium entry blockers against ouabain intoxication in anesthetized guinea pigs. Cardiovasc. Pharmacol. 8:1986;1009-1010.
43. Goldberger J.J., Aronson R.S. Effects of verapamil on ventricular tachycardia induced by ouabain in guinea pigs. Pace-Pacing Clin. Electrophysiol. 15:1992;162-163.
44. 2+ overload with R56865 protects against cardiac arrhythmias elicited by ouabain in vivo in guinea pigs. Eur. J. Pharmacol. 235:1993;89-93.